Description

3-[2,4-Bis[(3S)-3-Methylmorpholin-4-Yl]Pyrido[2,3-D]Pyrimidin-7-Yl]Benzoic Acid is a high-purity, advanced pharmaceutical intermediate featuring a complex pyrido[2,3-d]pyrimidin-7-yl benzoic acid core substituted with chiral 3-methylmorpholine groups. This compound matters as a critical building block in the synthesis of targeted kinase inhibitors, offering precise stereochemistry essential for biological activity. Pharmaceutical R&D and contract manufacturing organizations (CMOs) need this material for developing next-generation oncology and anti-inflammatory therapeutics.

Application

• Pharmaceutical Intermediate: A key precursor in the synthesis of novel, small-molecule kinase inhibitors for targeted cancer therapies.
• Oncology Drug Development: Used in research and development of compounds targeting specific protein kinases involved in tumor growth and proliferation.
• Anti-inflammatory Agent Synthesis: Serves as a core scaffold for developing potent and selective anti-inflammatory drugs.
• Biochemical Research: Employed as a reference standard or probe in enzymatic assays and structure-activity relationship (SAR) studies.
• Preclinical Candidate Optimization: Utilized by medicinal chemists for lead optimization and analog synthesis to improve drug-like properties.
• Contract Manufacturing & Scale-up: Supplied to CMOs for cGMP-compliant production of active pharmaceutical ingredients (APIs) under development.

Basic Information

Item	Details
Product Name	3-[2,4-Bis[(3S)-3-Methylmorpholin-4-Yl]Pyrido[2,3-D]Pyrimidin-7-Yl]Benzoic Acid
CAS No.	1009298-69-4
Molecular Formula	C28H31N5O4
Molecular Weight	501.58 g/mol
Synonyms	3-[2,4-Bis[(3S)-3-Methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]benzoic acid; 3-(2,4-Bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)benzoic acid; 1009298-69-4; UNII-6L8K6P8T2I; 6L8K6P8T2I; Benzoic acid, 3-[2,4-bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-; BDBM50164857; AKOS025310626.
EINECS	Contact for details

Quality Control

Our 3-[2,4-Bis[(3S)-3-Methylmorpholin-4-Yl]Pyrido[2,3-D]Pyrimidin-7-Yl]Benzoic Acid is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing, including chiral HPLC for enantiomeric purity and NMR for structural confirmation, to ensure compliance with research and development standards. Certificates of Analysis (COA) detailing purity, identity, and impurity profiles are available upon request to support your regulatory and R&D documentation needs.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature (15-25°C) in a dry, well-ventilated area. This compound is light-sensitive (store away from light) and may be hygroscopic (moisture-sensitive); prolonged exposure to air or moisture should be avoided.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (HPLC)	Conforms
Identification (IR)	Conforms
Purity (HPLC)	≥ 97.0%
Chiral Purity (Chiral HPLC)	≥ 98.0% ee
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.5%
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.